Purpose: The aim of this study was to evaluate the efficacy of XEN Gel Stent implantation in the treatment of primary open-angle glaucoma (POAG) and pseudoexfoliation glaucoma (XFG) regarding the reduction of intraocular pressure (IOP) and number of IOP-lowering medications over 2 years.
Methods: In this retrospective, observational, single-centre study, patients with POAG or XFG underwent implantation of the XEN Gel Stent with or without combined phacoemulsification. Changes in mean IOP, mean number of IOP-lowering medications, number of postoperative interventions, complete or qualified surgical success rate (defined as IOP < 18 mmHg without or with IOP-lowering medication, respectively) and complete surgical failure rate (defined as the necessity of a glaucoma-related secondary surgical intervention or loss of light perception) were assessed 12 months (12M) and 24 months (24M) postoperatively.
Results: Seventy-nine eyes of 63 patients with open-angle glaucoma were included in the study (71% POAG, 29% XFG). Before surgery, mean IOP was 23.4 ± 7.9 mmHg. IOP was 14.6 ± 3.6 mmHg 12 months postoperatively (-31% from baseline, 95% CI -42% to -20%, n = 30, p < 0.001) and 14.8 ± 4.4 mmHg 24 months postoperatively (-29% from baseline, 95% CI -30% to -41%, n = 28, p < 0.001). Mean number of IOP-lowering medications was significantly reduced from 2.7 ± 1.1 before surgery to 1.0 ± 1.2 (-69%, 95% CI -89% to 46%, p < 0.001) 12 months after surgery and 1.0 ± 1.2 (-64%, 95% CI -91% to -36%, p < 0.001) at 24 months after surgery. Complete surgical success was achieved in 39% (12M) and 34% (24M) of patients and qualified success in 29% (12M) and 27% (24M). 13 (16%) eyes were classified as complete surgical failure. In 62% of the patients needling procedures had to be performed.
Conclusion: The XEN Gel Stent is an efficacious minimal invasive glaucoma surgery for primary open-angle and pseudoexfoliation glaucoma, resulting in significant reduction of IOP and a reduction in glaucoma medications from baseline in two-third of treated patients with 2-year follow-up. Frequent follow-up examinations were mandatory to identify early and late bleb failure and additional needling procedures were necessary to reestablish aqueous flow.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359400 | PMC |
| http://dx.doi.org/10.1111/aos.14627 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing XEN microstent's one-year efficacy: independent of site variability.
Int J Ophthalmol
January 2025
Department of Ophthalmology, University of Leipzig, Liebigstrasse 10-14, Leipzig 04103, Germany.
Aim: To evaluate the short-term efficacy of XEN45 Gel Stent (XEN) implantation for primary open angle glaucoma (POAG) and pseudoexfoliation (PEX) glaucoma across two university eye clinics, aiming to assess the impact of varying center-specific protocols during the first postoperative year.
Methods: We retrospectively examined 282 patients (183 in center 1, 99 in center 2), who underwent XEN microstent implantation for uncontrolled POAG or PEX glaucoma. Parameters including intraocular pressure (IOP), IOP-lowering medication count, best corrected visual acuity (BCVA), and postoperative complications were evaluated over 12mo.
Macaroni necklace technique - Removal of a Xen gel stent.
Am J Ophthalmol Case Rep
December 2024
Casey Eye Institute at Oregon Health and Science University, 515 SW Campus Dr., Portland, OR, 97239, USA.
This video demonstrates the novel "macaroni necklace" technique for removing a Xen gel stent. The technique allows for complete removal of the stent without the hydrated and soft pieces from tearing apart. In this case, the stent was the nidus for endophthalmitis, and complete removal is necessary for prevention of future infections.
View Article and Find Full Text PDFClinical outcomes of Xen 45 gel stent implantation(Ab externo, open conjunctival approach) versus Trabeculectomy: A real world study.
Korean J Ophthalmol
December 2024
Department of Ophthalmology, Institute of Vision Research, Severance Eye Hospital, Yonsei University College of Medicine, South Korea.
Article Synopsis
- The study compared clinical outcomes of Xen 45 gel stent surgery and trabeculectomy in glaucoma patients, analyzing data from 62 eyes treated with Xen and 78 eyes with trabeculectomy over specific periods.
- Results showed a lower complete success rate for Xen (33.9%) compared to trabeculectomy (57.7%), along with higher postoperative intraocular pressure and more glaucoma medications needed in the Xen group; however, it had fewer complications (0% vs. 16.7%) and shorter operation time.
- Both surgical methods yielded similar postoperative best corrected visual acuity but differed in success rates, medication requirements, and safety profiles, indicating that while Xen may be quicker and safer
Transconjunctival XEN® 45 Gel Stent Implantation: Efficacy and Safety of a New Surgical Technique.
J Curr Glaucoma Pract
October 2024
Department of Ophthalmology, Hospital of San Severino Marche, AV3- Asur Marche, Macerata, Italy.
Article Synopsis
- This study aimed to assess the effectiveness and safety of a new surgical method called transconjunctival XEN® 45 gel stent implantation in treating primary open-angle glaucoma (POAG).
- A total of 31 patients underwent the procedure, experiencing an average decrease in intraocular pressure from 25.3 mm Hg pre-surgery to 15.9 mm Hg post-surgery, with most not needing additional medications by the one-month follow-up.
- The results suggest that this surgical technique is both safe and effective, offering a timely alternative for patients with POAG needing surgical intervention earlier in their treatment process.
Three-Year Results of XEN-45 Implantation for Glaucoma Secondary to Fuchs Uveitis Syndrome, Intermediate Uveitis, and Juvenile Idiopathic Arthritis-Related Anterior Uveitis.
Ocul Immunol Inflamm
November 2024
Centre for Ophthalmology, University Hospital Tuebingen, Tuebingen, Germany.
Purpose: To investigate the long-term outcomes of XEN-45 implantation for glaucoma secondary to Fuchs uveitis syndrome (FUS), juvenile idiopathic arthritis (JIA)-related anterior uveitis and intermediate uveitis (IU).
Methods: This retrospective study evaluated 19 eyes with FUS, 10 eyes with JIA, and nine eyes with IU that underwent XEN-45 Gel Stent implantation. The primary outcome measure was 3-year surgical success, defined as a ≥20% reduction in intraocular pressure (IOP), with a target IOP of 6-21 mmHg.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!